Abstract:Advanced glycation end products (AGEs) arise from the Maillard reaction between dicarbonyls and proteins, nucleic acids, or specific lipids. Notably, AGEs are linked to aging and implicated in various disorders, spanning from cancer to neurodegenerative diseases. While dicarbonyls like methylglyoxal preferentially target arginine residues, lysine-derived AGEs, such as N(6)-(1-carboxymethyl)lysine (CML) and N(6)-(1-carboxyethyl)lysine (CEL), are also abundant. Predicting protein glycation in vivo proves challenging due to the intricate nature of glycation reactions. In vitro, glycation is difficult to control, especially in proteins that harbor multiple glycation-prone amino acids. α-synuclein (aSyn), pivotal in Parkinson's disease and synucleinopathies, has 15 lysine residues and is known to become glycated at multiple lysine sites. To understand the influence of glycation in specific regions of aSyn on its behavior, a strategy for site-specific glycated protein production is imperative. To fulfill this demand, we devised a synthetic route integrating solid-phase peptide synthesis, orthogonal protection of amino acid side-chain functionalities, and reductive amination strategies. This methodology yielded two disease-related N-terminal peptide fragments, each featuring five and six CML and CEL modifications, alongside a full-length aSyn protein containing a site-selective E46CEL modification. Our synthetic approach facilitates the broad introduction of glycation motifs at specific sites, providing a foundation for generating glycated forms of synucleinopathy-related and other disease-relevant proteins.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a chemical synthesis method to achieve site - specific glycosylation modification of α - synuclein (α - synuclein, aSyn) and its fragments. Specifically, the researchers aim to synthesize aSyn peptides containing a specific number and position of Advanced Glycation End Products (AGEs) through Solid - Phase Peptide Synthesis (SPPS), side - chain orthogonal protection, and reductive amination techniques on resins. These AGEs include N(6)-(1 - carboxymethyl)lysine (CML) and N(6)-(1 - carboxyethyl)lysine (CEL) modifications. In addition, the study also attempts to synthesize the full - length aSyn protein through Native Chemical Ligation (NCL) technology and introduce a specific CEL modification at the glutamate residue at position 46 to mimic the effect of the E46K mutation associated with familial Parkinson's disease. ### Research Background α - synuclein (aSyn) plays a crucial role in Parkinson's disease (PD) and other related synucleinopathies. This protein is prone to misfolding and self - aggregation, forming high - molecular - weight species, and ultimately leading to the formation of Lewy bodies. Post - Translational Modifications (PTMs) of proteins, such as glycosylation, have a significant impact on the aggregation behavior and toxicity of aSyn. However, current in vitro glycosylation methods lack specificity and are unable to selectively modify multiple defined positions in the protein sequence. ### Main Objectives 1. **Develop a Synthesis Method**: Design and implement a synthesis strategy that can introduce CML and CEL modifications on multiple lysine residues of aSyn peptides simultaneously. 2. **Synthesize Specifically Modified Peptides**: Synthesize two N - terminal aSyn fragments, each containing five and six CML or CEL modifications respectively. 3. **Synthesize the Full - Length aSyn Protein**: Synthesize the full - length aSyn protein through NCL technology and introduce a specific CEL modification at the glutamate residue at position 46 to mimic the effect of the E46K mutation. ### Methods - **Solid - Phase Peptide Synthesis (SPPS)**: Use Fmoc - Lys(Alloc)-OH as the protected lysine building block to synthesize peptides. - **Side - Chain Orthogonal Protection**: Selectively remove the Alloc protecting group and then perform a reductive amination reaction to introduce CML or CEL modifications. - **Native Chemical Ligation (NCL)**: Connect the synthesized peptides into the full - length aSyn protein through NCL technology. ### Results - Successfully synthesized aSyn peptides containing multiple CML and CEL modifications. - Successfully synthesized the full - length aSyn protein through NCL technology and introduced a specific CEL modification at the glutamate residue at position 46. - Verified the secondary structure characteristics of the modified aSyn proteins and peptides through Circular Dichroism (CD) analysis, indicating that these modifications did not significantly change the overall structure of aSyn. ### Conclusion This study has developed an efficient and controllable method for introducing multi - site - specific glycosylation modifications in aSyn and its fragments. This method provides an important tool for studying the impact of glycosylation on the aggregation behavior and function of aSyn, and is helpful for in - depth understanding of the pathogenesis of neurodegenerative diseases such as Parkinson's disease.

Chemical synthesis of site-selective advanced glycation end products in α-synuclein and its fragments

Blue native/SDS-PAGE combined with iTRAQ analysis reveals advanced glycation end-product-induced changes of synaptosome proteins in C57 BL/6 mice

Synthesis and Semi-Synthesis of Alpha-Synuclein: Insight into the Chemical Complexity of Synucleinopathies

Glycation of alpha-synuclein enhances aggregation and neuroinflammatory responses

Enzymatic O-GlcNAcylation of Α-Synuclein Reduces Aggregation and Increases SDS-resistant Soluble Oligomers

RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions

Mapping sites of carboxymethyllysine modification on proteins reveals its consequences for proteostasis and cell proliferation

Elucidating the Role of C-terminal Post-Translational Modifications Using Protein Semisynthesis Strategies: Α-Synuclein Phosphorylation at Tyrosine 125.

Site-specific Chemoproteomic Profiling of Targets of Glyoxal

A targetable N-terminal motif orchestrates α-Synuclein oligomer to fibril conversion

Identification of a Specific Α-Synuclein Peptide (Α-Syn 29-40) Capable of Eliciting Microglial Superoxide Production to Damage Dopaminergic Neurons

Elucidating the mechanisms of α-Synuclein-lipid interactions using site-directed mutagenesis

Combining non-canonical amino acid mutagenesis and native chemical ligation for multiply modifying proteins: A case study of α-synuclein post-translational modifications

Insight into the Effect of Methylglyoxal on the Conformation, Function, and Aggregation Propensity of α‐Synuclein

Identification Of Age-Precursors Andage Formation In Glycation-Induced Bsa Peptides

Rational Generation of Monoclonal Antibodies Selective for Pathogenic Forms of Alpha-Synuclein

Glycation Produces Topologically Different α-Synuclein Oligomeric Strains and Modulates Microglia Response via the NLRP3-Inflammasome Pathway

Advanced Glycation End Products in Neurodegenerative Diseases

Age- and Brain Region-Dependent Α-Synuclein Oligomerization is Attributed to Alterations in Intrinsic Enzymes Regulating Α-Synuclein Phosphorylation in Aging Monkey Brains

Advanced glycation end-product crosslinking activates a type VI secretion system phospholipase effector protein

Discovery of Small-Molecule Degraders for Alpha-Synuclein Aggregates